The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B

  • Kim, Sung Eun (Department of Internal Medicine, Hallym University Sacred Heart Hospital)
  • Received : 2017.06.14
  • Accepted : 2017.06.19
  • Published : 2017.07.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-592. https://doi.org/10.1016/S0140-6736(09)60207-5
  2. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993;262:369-370. https://doi.org/10.1126/science.8211155
  3. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. https://doi.org/10.1001/jama.295.1.65
  4. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686. https://doi.org/10.1053/j.gastro.2005.11.016
  5. Lin CL, Kao JH. Hepatitis B viral factors and treatment responses in chronic hepatitis B. J Formos Med Assoc 2013;112:302-311. https://doi.org/10.1016/j.jfma.2013.02.001
  6. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011: a core group report. J Hepatol 2011;55:1121-1131. https://doi.org/10.1016/j.jhep.2011.06.006
  7. Su TH, Hsu CS, Chen CL, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther 2010;15:1133-1139. https://doi.org/10.3851/IMP1696
  8. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010;139:483-490. https://doi.org/10.1053/j.gastro.2010.04.052
  9. Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011;141:517-525.e1-2. https://doi.org/10.1053/j.gastro.2011.04.046
  10. Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009;46:117-123. https://doi.org/10.1016/j.jcv.2009.07.005
  11. Lee MH, Lee DM, Kim SS, Cheong JY, Cho SW. Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B. J Med Virol 2011;83:1178-1186. https://doi.org/10.1002/jmv.22089
  12. Cho JY, Sohn W, Sinn DH, et al. Long-term real-world entecavir therapy in treatment-naive hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. Korean J Intern Med 2017;32:636-646. https://doi.org/10.3904/kjim.2016.096
  13. Lee MH, Yang HI, Liu J, et al. Prediction models of longterm cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013;58:546-554. https://doi.org/10.1002/hep.26385
  14. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142:1140-1149.e3. https://doi.org/10.1053/j.gastro.2012.02.007

Cited by

  1. Authors’ response: Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection vol.28, pp.3, 2017, https://doi.org/10.1111/jvh.13450